The estimated Net Worth of Jeffrey S Bornstein is at least $5.73 million dollars as of 26 April 2022. Jeffrey Bornstein owns over 5,000 units of AlloVir stock worth over $30,550 and over the last 11 years Jeffrey sold ALVR stock worth over $5,698,100.
Jeffrey has made over 26 trades of the AlloVir stock since 2013, according to the Form 4 filled with the SEC. Most recently Jeffrey bought 5,000 units of ALVR stock worth $23,200 on 26 April 2022.
The largest trade Jeffrey's ever made was exercising 200,000 units of AlloVir stock on 27 July 2017 worth over $152,000. On average, Jeffrey trades about 19,508 units every 78 days since 2013. As of 26 April 2022 Jeffrey still owns at least 40,197 units of AlloVir stock.
You can see the complete history of Jeffrey Bornstein stock trades at the bottom of the page.
Jeffrey's mailing address filed with the SEC is C/O ALLOVIR, INC., 1100 WINTER STREET, WALTHAM, MA, 02451.
Over the last 4 years, insiders at AlloVir have traded over $46,310,999 worth of AlloVir stock and bought 5,850,170 units worth $60,516,413 . The most active insiders traders include Sciences, Inc. Gilead, Group, Llc Green Jeremy Red... et Ansbert Gadicke. On average, AlloVir executives and independent directors trade stock every 9 days with the average trade being worth of $40,307. The most recent stock trade was executed by Diana Brainard on 20 August 2024, trading 5,390 units of ALVR stock currently worth $3,989.
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108 to treat human herpesvirus-8, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's diseases. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
AlloVir executives and other stock owners filed with the SEC include: